businesspress24.com - Ablynx to Present at 2013 J.P. Morgan Healthcare Conference
 

Ablynx to Present at 2013 J.P. Morgan Healthcare Conference

ID: 1184769

(firmenpresse) - GHENT, BELGIUM -- (Marketwire) -- 01/07/13 -- (EURONEXT BRUSSELS: ABLX) today announces it will present at the 31st Annual J.P. Morgan Healthcare Conference in San Francisco, California on Thursday, 10th January 2013 at 12:00 p.m. PST (21:00 p.m. CET).

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will provide an update on the Company's late-stage proprietary Nanobody® programmes, the Company's growth and partnering strategy and the outlook for the near term future.

The presentation will be webcast live and can be accessed on the day via the Ablynx website at . A replay of the webcast will be available on the Company's website for 30 days following the presentation. To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

Ablynx is a biopharmaceutical company engaged in the discovery and development of Nanobodies®, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious human diseases, including inflammation, haematology, oncology and pulmonary disease. Today, the Company has approximately 25 programmes in the pipeline and five Nanobodies at clinical development stage. Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies including Boehringer Ingelheim, Merck KGaA, Novartis and Merck & Co. The Company is headquartered in Ghent, Belgium.

More information can be found on .

press release in pdf format:



Dr Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193
+32 (0)473 39 50 68
e:

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:
Follow us on Twitter (at)AblynxABLX

Mary-Jane Elliott
Amber Bielecka
Claire Dickinson




t: +44 207 920 2330
e:


Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:



Leseranfragen:



PresseKontakt / Agentur:



drucken  als PDF  an Freund senden  Cytta Completes Mobile Monitoring Technology Pilot Program and Begins Licensing Discussions
Oral Cancer Prevention International and CDx Laboratories Merge to Form CDx Diagnostics
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 07.01.2013 - 12:14 Uhr
Sprache: Deutsch
News-ID 1184769
Anzahl Zeichen: 0

contact information:
Contact person:
Town:

GHENT, BELGIUM


Phone:

Kategorie:

Healthcare


Anmerkungen:


Diese Pressemitteilung wurde bisher 121 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Ablynx to Present at 2013 J.P. Morgan Healthcare Conference
"
steht unter der journalistisch-redaktionellen Verantwortung von

Ablynx (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).


Alle Meldungen von Ablynx



 

Who is online

All members: 10 578
Register today: 0
Register yesterday: 4
Members online: 0
Guests online: 64


Don't have an account yet? You can create one. As registered user you have some advantages like theme manager, comments configuration and post comments with your name.